Relapsed/Refractory Follicular Lymphoma: EZH2- and PIK3-Targeted Therapies

A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.

Related Keywords

,Treatment Approach ,Expanding Treatment Options ,Refractory Follicular Lymphoma ,Follicular Lymphoma ,Relapsed Refractory Fl ,Relapsed Refractory Follicular Lymphoma ,Fl Cancer ,Ezh2 Mutation ,Ezh2 Testing ,Tazemetostat ,Adverse Events ,Safety Profile ,Efficacy Data ,Patient Selection ,Patient Monitoring ,Patient Followup ,Copanlisib ,Pi3k Inhibitor ,Pi3ki ,